These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25858859)

  • 1. An experimental subunit vaccine based on Bluetongue virus 4 VP2 protein fused to an antigen-presenting cells single chain antibody elicits cellular and humoral immune responses in cattle, guinea pigs and IFNAR(-/-) mice.
    Legisa DM; Perez Aguirreburualde MS; Gonzalez FN; Marin-Lopez A; Ruiz V; Wigdorovitz A; Martinez-Escribano JA; Ortego J; Dus Santos MJ
    Vaccine; 2015 May; 33(22):2614-9. PubMed ID: 25858859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice.
    Marín-López A; Otero-Romero I; de la Poza F; Menaya-Vargas R; Calvo-Pinilla E; Benavente J; Martínez-Costas JM; Ortego J
    Antiviral Res; 2014 Oct; 110():42-51. PubMed ID: 25057758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus.
    Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Benavente J; Brun A; Martínez-Costas JM; Ortego J
    Antiviral Res; 2017 Jun; 142():55-62. PubMed ID: 28322923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen.
    Franceschi V; Capocefalo A; Calvo-Pinilla E; Redaelli M; Mucignat-Caretta C; Mertens P; Ortego J; Donofrio G
    Vaccine; 2011 Apr; 29(16):3074-82. PubMed ID: 21320537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant bluetongue virus with hemagglutinin epitopes in VP2 has potential as a labeled vaccine.
    Guo Y; Huang L; Bi K; Xu Q; Bu Z; Wang F; Sun E
    Vet Microbiol; 2020 Sep; 248():108825. PubMed ID: 32891953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Comtet L; Lövgren Bengtsson K; Pringle J; Zientara S; Valarcher JF
    Clin Vaccine Immunol; 2013 Aug; 20(8):1115-22. PubMed ID: 23720365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.
    Jiménez-Cabello L; Utrilla-Trigo S; Calvo-Pinilla E; Lorenzo G; Illescas-Amo M; Benavides J; Moreno S; Marín-López A; Nogales A; Ortego J
    Front Immunol; 2024; 15():1440407. PubMed ID: 39072326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.
    Li J; Yang T; Xu Q; Sun E; Feng Y; Lv S; Zhang Q; Wang H; Wu D
    Appl Microbiol Biotechnol; 2015 Oct; 99(20):8643-52. PubMed ID: 26048472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals.
    Anderson J; Bréard E; Lövgren Bengtsson K; Grönvik KO; Zientara S; Valarcher JF; Hägglund S
    Clin Vaccine Immunol; 2014 Mar; 21(3):443-52. PubMed ID: 24451327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an APC-targeted multivalent E2-based vaccine against Bovine Viral Diarrhea Virus types 1 and 2.
    Pecora A; Malacari DA; Perez Aguirreburualde MS; Bellido D; Nuñez MC; Dus Santos MJ; Escribano JM; Wigdorovitz A
    Vaccine; 2015 Sep; 33(39):5163-71. PubMed ID: 26279338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunisation with bacterial expressed VP2 and VP5 of bluetongue virus (BTV) protect α/β interferon-receptor knock-out (IFNAR(-/-)) mice from homologous lethal challenge.
    Mohd Jaafar F; Belhouchet M; Vitour D; Adam M; Breard E; Zientara S; Mertens PP; Attoui H
    Vaccine; 2014 Jul; 32(32):4059-67. PubMed ID: 24886956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of a conserved region of bluetongue virus protein VP2 in cross-neutralisation of bluetongue virus serotypes.
    Jyothi SJ; Patil SR; Reddy NY; Panduranga RP; Madala U; Prakash GM; Putty K
    Onderstepoort J Vet Res; 2020 Oct; 87(1):e1-e6. PubMed ID: 33054261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.
    Calvo-Pinilla E; Rodríguez-Calvo T; Sevilla N; Ortego J
    Vaccine; 2009 Dec; 28(2):437-45. PubMed ID: 19857449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep.
    Mokoena NB; Moetlhoa B; Rutkowska DA; Mamputha S; Dibakwane VS; Tsekoa TL; O'Kennedy MM
    Vaccine; 2019 Sep; 37(41):6068-6075. PubMed ID: 31471154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.
    Jabbar TK; Calvo-Pinilla E; Mateos F; Gubbins S; Bin-Tarif A; Bachanek-Bankowska K; Alpar O; Ortego J; Takamatsu HH; Mertens PP; Castillo-Olivares J
    PLoS One; 2013; 8(4):e60574. PubMed ID: 23593251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus.
    Top S; Foucras G; Deplanche M; Rives G; Calvalido J; Comtet L; Bertagnoli S; Meyer G
    Vaccine; 2012 Feb; 30(9):1609-16. PubMed ID: 22244980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.